BLOODPAC
@bloodpac.bsky.social
Accelerating the development and validation of #liquidbiopsy assays to improve the outcomes of patients with #cancer. Not-for-profit.
We were proud to join #AMP2025!
Our Executive Director, Lauren Leiman, moderated “Demystifying MRD with BLOODPAC,” joined by leaders from Illumina, Harvard, BMS & BLOODPAC to discuss best practices and innovation in cancer monitoring. #MRD #LiquidBiopsy #Oncology
Our Executive Director, Lauren Leiman, moderated “Demystifying MRD with BLOODPAC,” joined by leaders from Illumina, Harvard, BMS & BLOODPAC to discuss best practices and innovation in cancer monitoring. #MRD #LiquidBiopsy #Oncology
November 13, 2025 at 8:21 PM
We were proud to join #AMP2025!
Our Executive Director, Lauren Leiman, moderated “Demystifying MRD with BLOODPAC,” joined by leaders from Illumina, Harvard, BMS & BLOODPAC to discuss best practices and innovation in cancer monitoring. #MRD #LiquidBiopsy #Oncology
Our Executive Director, Lauren Leiman, moderated “Demystifying MRD with BLOODPAC,” joined by leaders from Illumina, Harvard, BMS & BLOODPAC to discuss best practices and innovation in cancer monitoring. #MRD #LiquidBiopsy #Oncology
We’re excited to welcome nRichDX as BLOODPAC’s newest member! Their patented Revolution Sample Prep System™ aims to advance liquid biopsy by maximizing recovery of rare analytes to improve diagnostic accuracy.
🔗 nrichdx.com
🔗 nrichdx.com
November 13, 2025 at 3:45 PM
We’re excited to welcome nRichDX as BLOODPAC’s newest member! Their patented Revolution Sample Prep System™ aims to advance liquid biopsy by maximizing recovery of rare analytes to improve diagnostic accuracy.
🔗 nrichdx.com
🔗 nrichdx.com
Excited to share that BLOODPAC Executive Director, Lauren Leiman, will moderate “Demystifying MRD with BLOODPAC” at #AMP2025 on Nov 12, 4–4:50 PM in Boston!
Join experts from Illumina, HMS, BMS & BLOODPAC to explore the future of MRD testing.
#LiquidBiopsy #Oncology
Join experts from Illumina, HMS, BMS & BLOODPAC to explore the future of MRD testing.
#LiquidBiopsy #Oncology
November 12, 2025 at 4:05 PM
Excited to share that BLOODPAC Executive Director, Lauren Leiman, will moderate “Demystifying MRD with BLOODPAC” at #AMP2025 on Nov 12, 4–4:50 PM in Boston!
Join experts from Illumina, HMS, BMS & BLOODPAC to explore the future of MRD testing.
#LiquidBiopsy #Oncology
Join experts from Illumina, HMS, BMS & BLOODPAC to explore the future of MRD testing.
#LiquidBiopsy #Oncology
Huge thanks to all who joined our 4th Annual BLOODPAC New Frontiers Seminar: “New Frontiers in Therapy Selection: Beyond DNA Mutations.” Inspiring talks & discussions on the future of precision oncology! Highlights coming soon! #LiquidBiopsy #TherapySelection #PrecisionOncology #BLOODPAC
November 6, 2025 at 5:00 PM
Huge thanks to all who joined our 4th Annual BLOODPAC New Frontiers Seminar: “New Frontiers in Therapy Selection: Beyond DNA Mutations.” Inspiring talks & discussions on the future of precision oncology! Highlights coming soon! #LiquidBiopsy #TherapySelection #PrecisionOncology #BLOODPAC
Thank you to ISLB and Dr. Christian Rolfo for an inspiring 7th Annual Congress of Liquid Biopsy! Our Executive Director, Lauren Leiman, joined experts from BLOODPAC member organizations—Thermo Fisher, Guardant, Foundation Medicine/Roche, and Natera—to discuss translation of LBx into the clinic.
November 4, 2025 at 4:26 PM
Thank you to ISLB and Dr. Christian Rolfo for an inspiring 7th Annual Congress of Liquid Biopsy! Our Executive Director, Lauren Leiman, joined experts from BLOODPAC member organizations—Thermo Fisher, Guardant, Foundation Medicine/Roche, and Natera—to discuss translation of LBx into the clinic.
We’re bringing together an outstanding lineup for this year’s BLOODPAC New Frontiers Seminar. Don’t miss out on a great discussion on how multimodal data can advance therapy selection.
🗓️ November 5 | 1–3 PM ET
🎟️ Register here: bit.ly/BP-New-Front...
🗓️ November 5 | 1–3 PM ET
🎟️ Register here: bit.ly/BP-New-Front...
October 29, 2025 at 3:06 PM
We’re bringing together an outstanding lineup for this year’s BLOODPAC New Frontiers Seminar. Don’t miss out on a great discussion on how multimodal data can advance therapy selection.
🗓️ November 5 | 1–3 PM ET
🎟️ Register here: bit.ly/BP-New-Front...
🗓️ November 5 | 1–3 PM ET
🎟️ Register here: bit.ly/BP-New-Front...
Last year @ New Frontiers Seminar, Dr. Robert Tell (Tempus AI) showed how multi-omic + multimodal data (ctDNA, RNA, imaging, EHRs) can push liquid biopsy beyond single-analyte limits.
👉 2025 seminar registration: bit.ly/BP-New-Front...
👉 Watch the 2024 seminar: www.bloodpac.org/beyond-ctdna
👉 2025 seminar registration: bit.ly/BP-New-Front...
👉 Watch the 2024 seminar: www.bloodpac.org/beyond-ctdna
October 23, 2025 at 2:31 PM
Last year @ New Frontiers Seminar, Dr. Robert Tell (Tempus AI) showed how multi-omic + multimodal data (ctDNA, RNA, imaging, EHRs) can push liquid biopsy beyond single-analyte limits.
👉 2025 seminar registration: bit.ly/BP-New-Front...
👉 Watch the 2024 seminar: www.bloodpac.org/beyond-ctdna
👉 2025 seminar registration: bit.ly/BP-New-Front...
👉 Watch the 2024 seminar: www.bloodpac.org/beyond-ctdna
⏳ Just a few weeks away!
The BLOODPAC New Frontiers Seminar returns on November 5. This year, we’re tackling one of the most important frontiers in precision oncology: using multimodal data for therapy selection.
Save your spot today ➡️ bit.ly/BP-New-Front...
The BLOODPAC New Frontiers Seminar returns on November 5. This year, we’re tackling one of the most important frontiers in precision oncology: using multimodal data for therapy selection.
Save your spot today ➡️ bit.ly/BP-New-Front...
October 21, 2025 at 3:02 PM
⏳ Just a few weeks away!
The BLOODPAC New Frontiers Seminar returns on November 5. This year, we’re tackling one of the most important frontiers in precision oncology: using multimodal data for therapy selection.
Save your spot today ➡️ bit.ly/BP-New-Front...
The BLOODPAC New Frontiers Seminar returns on November 5. This year, we’re tackling one of the most important frontiers in precision oncology: using multimodal data for therapy selection.
Save your spot today ➡️ bit.ly/BP-New-Front...
In Berlin for #ESMO25, BLOODPAC’s Global Regulatory Working Group hosted a dinner uniting leaders to strengthen collaboration & advance #liquidbiopsy integration and patient access across Europe. We’re grateful to everyone who joined us for an inspiring evening of partnership, purpose, and progress.
October 20, 2025 at 3:42 PM
In Berlin for #ESMO25, BLOODPAC’s Global Regulatory Working Group hosted a dinner uniting leaders to strengthen collaboration & advance #liquidbiopsy integration and patient access across Europe. We’re grateful to everyone who joined us for an inspiring evening of partnership, purpose, and progress.
New Frontiers throwback: Dr. Chris Douville (JHU) showed an analytical toolkit to build liquid biopsies, by tackling biomarker challenges + avoiding overfitting with smarter validation.
👉 2025 seminar registration: bit.ly/BP-New-Front...
👉 Watch the 2024 seminar: www.bloodpac.org/beyond-ctdna
👉 2025 seminar registration: bit.ly/BP-New-Front...
👉 Watch the 2024 seminar: www.bloodpac.org/beyond-ctdna
October 16, 2025 at 2:32 PM
New Frontiers throwback: Dr. Chris Douville (JHU) showed an analytical toolkit to build liquid biopsies, by tackling biomarker challenges + avoiding overfitting with smarter validation.
👉 2025 seminar registration: bit.ly/BP-New-Front...
👉 Watch the 2024 seminar: www.bloodpac.org/beyond-ctdna
👉 2025 seminar registration: bit.ly/BP-New-Front...
👉 Watch the 2024 seminar: www.bloodpac.org/beyond-ctdna
A little over a month since our Q3 meeting! Thanks to all who joined us at Exact Sciences in Madison. We worked hard, had fun, all while moving closer to our mission: making liquid biopsy accessible to all.
October 13, 2025 at 2:12 PM
A little over a month since our Q3 meeting! Thanks to all who joined us at Exact Sciences in Madison. We worked hard, had fun, all while moving closer to our mission: making liquid biopsy accessible to all.
Last year’s New Frontiers Seminar, Dr. Wendy Winckler (Droplet Biosciences) showed how multiomics + machine learning and lymph ctDNA can push liquid biopsy beyond ctDNA to boost sensitivity.
👉 Register for the 2025 seminar: bit.ly/BP-New-Front...
👉 Last year seminar: www.bloodpac.org/beyond-ctdna
👉 Register for the 2025 seminar: bit.ly/BP-New-Front...
👉 Last year seminar: www.bloodpac.org/beyond-ctdna
October 9, 2025 at 3:02 PM
Last year’s New Frontiers Seminar, Dr. Wendy Winckler (Droplet Biosciences) showed how multiomics + machine learning and lymph ctDNA can push liquid biopsy beyond ctDNA to boost sensitivity.
👉 Register for the 2025 seminar: bit.ly/BP-New-Front...
👉 Last year seminar: www.bloodpac.org/beyond-ctdna
👉 Register for the 2025 seminar: bit.ly/BP-New-Front...
👉 Last year seminar: www.bloodpac.org/beyond-ctdna
Meet the stellar lineup of speakers leading the conversation on multimodal data in therapy selection at our New Frontiers Seminar!
📆 𝙉𝙤𝙫𝙚𝙢𝙗𝙚𝙧 5 | 1–3 𝙋𝙈 𝙀𝙏
🎯 “𝙉𝙚𝙬 𝙁𝙧𝙤𝙣𝙩𝙞𝙚𝙧𝙨 𝙞𝙣 𝙏𝙝𝙚𝙧𝙖𝙥𝙮 𝙎𝙚𝙡𝙚𝙘𝙩𝙞𝙤𝙣: 𝘽𝙚𝙮𝙤𝙣𝙙 𝘿𝙉𝘼 𝙈𝙪𝙩𝙖𝙩𝙞𝙤𝙣𝙨”
👉 Register here: bit.ly/BP-New-Front...
📆 𝙉𝙤𝙫𝙚𝙢𝙗𝙚𝙧 5 | 1–3 𝙋𝙈 𝙀𝙏
🎯 “𝙉𝙚𝙬 𝙁𝙧𝙤𝙣𝙩𝙞𝙚𝙧𝙨 𝙞𝙣 𝙏𝙝𝙚𝙧𝙖𝙥𝙮 𝙎𝙚𝙡𝙚𝙘𝙩𝙞𝙤𝙣: 𝘽𝙚𝙮𝙤𝙣𝙙 𝘿𝙉𝘼 𝙈𝙪𝙩𝙖𝙩𝙞𝙤𝙣𝙨”
👉 Register here: bit.ly/BP-New-Front...
October 8, 2025 at 3:07 PM
Meet the stellar lineup of speakers leading the conversation on multimodal data in therapy selection at our New Frontiers Seminar!
📆 𝙉𝙤𝙫𝙚𝙢𝙗𝙚𝙧 5 | 1–3 𝙋𝙈 𝙀𝙏
🎯 “𝙉𝙚𝙬 𝙁𝙧𝙤𝙣𝙩𝙞𝙚𝙧𝙨 𝙞𝙣 𝙏𝙝𝙚𝙧𝙖𝙥𝙮 𝙎𝙚𝙡𝙚𝙘𝙩𝙞𝙤𝙣: 𝘽𝙚𝙮𝙤𝙣𝙙 𝘿𝙉𝘼 𝙈𝙪𝙩𝙖𝙩𝙞𝙤𝙣𝙨”
👉 Register here: bit.ly/BP-New-Front...
📆 𝙉𝙤𝙫𝙚𝙢𝙗𝙚𝙧 5 | 1–3 𝙋𝙈 𝙀𝙏
🎯 “𝙉𝙚𝙬 𝙁𝙧𝙤𝙣𝙩𝙞𝙚𝙧𝙨 𝙞𝙣 𝙏𝙝𝙚𝙧𝙖𝙥𝙮 𝙎𝙚𝙡𝙚𝙘𝙩𝙞𝙤𝙣: 𝘽𝙚𝙮𝙤𝙣𝙙 𝘿𝙉𝘼 𝙈𝙪𝙩𝙖𝙩𝙞𝙤𝙣𝙨”
👉 Register here: bit.ly/BP-New-Front...
🔬 The next #PreventCancerDialogue Virtual Series takes place on October 8, 2025 | 1–2:30 PM ET!
This session will examine how MRD improves prognosis and patient outcomes and more!
💻 Register today for free: pcf.elevate.gocadmium.com
This session will examine how MRD improves prognosis and patient outcomes and more!
💻 Register today for free: pcf.elevate.gocadmium.com
October 7, 2025 at 2:16 PM
🔬 The next #PreventCancerDialogue Virtual Series takes place on October 8, 2025 | 1–2:30 PM ET!
This session will examine how MRD improves prognosis and patient outcomes and more!
💻 Register today for free: pcf.elevate.gocadmium.com
This session will examine how MRD improves prognosis and patient outcomes and more!
💻 Register today for free: pcf.elevate.gocadmium.com
🎉 We’re thrilled to welcome @biomodal to the BLOODPAC community!
biomodal develops technologies and analytics that serve as research tools for life scientists and clinical developers.
👉 Want a deep dive into what they do? Learn more: biomodal.com
biomodal develops technologies and analytics that serve as research tools for life scientists and clinical developers.
👉 Want a deep dive into what they do? Learn more: biomodal.com
October 3, 2025 at 5:40 PM
🎉 We’re thrilled to welcome @biomodal to the BLOODPAC community!
biomodal develops technologies and analytics that serve as research tools for life scientists and clinical developers.
👉 Want a deep dive into what they do? Learn more: biomodal.com
biomodal develops technologies and analytics that serve as research tools for life scientists and clinical developers.
👉 Want a deep dive into what they do? Learn more: biomodal.com
Throwback to last year’s BLOODPAC New Frontiers Seminar: Dr. Sam Hanash (MD Anderson) showed how protein biomarkers can spot cancer risk earlier + guide personalized screening.
👉 Register to this year’s Seminar: bit.ly/BP-New-Front...
👉 Check out last year’s seminar: www.bloodpac.org/beyond-ctdna
👉 Register to this year’s Seminar: bit.ly/BP-New-Front...
👉 Check out last year’s seminar: www.bloodpac.org/beyond-ctdna
October 2, 2025 at 3:35 PM
Throwback to last year’s BLOODPAC New Frontiers Seminar: Dr. Sam Hanash (MD Anderson) showed how protein biomarkers can spot cancer risk earlier + guide personalized screening.
👉 Register to this year’s Seminar: bit.ly/BP-New-Front...
👉 Check out last year’s seminar: www.bloodpac.org/beyond-ctdna
👉 Register to this year’s Seminar: bit.ly/BP-New-Front...
👉 Check out last year’s seminar: www.bloodpac.org/beyond-ctdna
🌍 The BLOODPAC Global Regulatory WG published “Collaborations with EU Liquid Biopsy Initiatives” in the Journal of Liquid Biopsy!
👏 Thanks to the co-chairs & members.
Next up: a Berlin dinner at ESMO 2025 to advance global efforts. Read here: lnkd.in/giWczgsF
👏 Thanks to the co-chairs & members.
Next up: a Berlin dinner at ESMO 2025 to advance global efforts. Read here: lnkd.in/giWczgsF
October 1, 2025 at 9:55 PM
🌍 The BLOODPAC Global Regulatory WG published “Collaborations with EU Liquid Biopsy Initiatives” in the Journal of Liquid Biopsy!
👏 Thanks to the co-chairs & members.
Next up: a Berlin dinner at ESMO 2025 to advance global efforts. Read here: lnkd.in/giWczgsF
👏 Thanks to the co-chairs & members.
Next up: a Berlin dinner at ESMO 2025 to advance global efforts. Read here: lnkd.in/giWczgsF
📢 Join us for the 2025 #PreventCancerDialogue Virtual Series on October 8, 2025 | 1–2:30 PM ET!
Session: MRD in cancer - predicting relapse, guiding personalized care, and advancing research & clinical use.
✅ Free registration: pcf.elevate.gocadmium.com
Session: MRD in cancer - predicting relapse, guiding personalized care, and advancing research & clinical use.
✅ Free registration: pcf.elevate.gocadmium.com
October 1, 2025 at 2:50 PM
📢 Join us for the 2025 #PreventCancerDialogue Virtual Series on October 8, 2025 | 1–2:30 PM ET!
Session: MRD in cancer - predicting relapse, guiding personalized care, and advancing research & clinical use.
✅ Free registration: pcf.elevate.gocadmium.com
Session: MRD in cancer - predicting relapse, guiding personalized care, and advancing research & clinical use.
✅ Free registration: pcf.elevate.gocadmium.com
Our Brain Tumor WG has published MTDEs for CSF-based liquid biopsy: ascopubs.org/doi/10.1200/... and is now preparing its next project: a clinical study.
At our Q3 meeting, the group aligned on study parameters and is planning an in-person kickoff with collaborators.
Excited for what’s coming up!
At our Q3 meeting, the group aligned on study parameters and is planning an in-person kickoff with collaborators.
Excited for what’s coming up!
September 30, 2025 at 3:14 PM
Our Brain Tumor WG has published MTDEs for CSF-based liquid biopsy: ascopubs.org/doi/10.1200/... and is now preparing its next project: a clinical study.
At our Q3 meeting, the group aligned on study parameters and is planning an in-person kickoff with collaborators.
Excited for what’s coming up!
At our Q3 meeting, the group aligned on study parameters and is planning an in-person kickoff with collaborators.
Excited for what’s coming up!
Great session at the 7th ACTC last week! Our Executive Director, Lauren Leiman shared BLOODPAC’s perspective on early detection. Thanks to Bree Mitchell (Natera), Frank Diehl (Exact Sciences) & Peter Kuhn (USC) for insightful talks! And to Evi Lianidou & ACTC organizers for inviting us!
September 29, 2025 at 3:48 PM
Great session at the 7th ACTC last week! Our Executive Director, Lauren Leiman shared BLOODPAC’s perspective on early detection. Thanks to Bree Mitchell (Natera), Frank Diehl (Exact Sciences) & Peter Kuhn (USC) for insightful talks! And to Evi Lianidou & ACTC organizers for inviting us!
The MRD Strategic Steering Group, led by Angela Silvestro and Jim Godsey, used Q3 workshop time to refine BLOODPAC’s overall MRD strategy.
We revisited goals, assessed priorities in analytical and clinical validation, and set the direction as we work toward our 2027 Summit.
On to what's next!
We revisited goals, assessed priorities in analytical and clinical validation, and set the direction as we work toward our 2027 Summit.
On to what's next!
September 29, 2025 at 2:47 PM
The MRD Strategic Steering Group, led by Angela Silvestro and Jim Godsey, used Q3 workshop time to refine BLOODPAC’s overall MRD strategy.
We revisited goals, assessed priorities in analytical and clinical validation, and set the direction as we work toward our 2027 Summit.
On to what's next!
We revisited goals, assessed priorities in analytical and clinical validation, and set the direction as we work toward our 2027 Summit.
On to what's next!
The MRD Clinical Validation Working Group, led by Dan Norton and Carol Pena, has submitted our FDA pre-submission.
At our Q3 meeting, they took time to realign and set the course for the next phase of collaborative efforts in advancing MRD clinical validation. More updates soon!
At our Q3 meeting, they took time to realign and set the course for the next phase of collaborative efforts in advancing MRD clinical validation. More updates soon!
September 26, 2025 at 2:59 PM
The MRD Clinical Validation Working Group, led by Dan Norton and Carol Pena, has submitted our FDA pre-submission.
At our Q3 meeting, they took time to realign and set the course for the next phase of collaborative efforts in advancing MRD clinical validation. More updates soon!
At our Q3 meeting, they took time to realign and set the course for the next phase of collaborative efforts in advancing MRD clinical validation. More updates soon!
Big news from BLOODPAC’s Clinician Education and Access Working Group! At our Q3 2025 meeting, they announced a multi-year effort to answer a critical question: how are clinicians using liquid biopsy? Stay tuned for their findings, with a manuscript planned for early 2027.
September 25, 2025 at 3:28 PM
Big news from BLOODPAC’s Clinician Education and Access Working Group! At our Q3 2025 meeting, they announced a multi-year effort to answer a critical question: how are clinicians using liquid biopsy? Stay tuned for their findings, with a manuscript planned for early 2027.
Our Analytical Validation (AV) efforts are on a roll. Check our Q3 updates:
✅bTMB AV paper = just published bit.ly/BP-bTMB
✅MRD tumor-informed AV paper = under peer review
✅NGS ctDNA AV protocols v2.0 = almost ready to submit
Next: tumor-agnostic #MRD AV pre-sub. More to come soon!
#LiquidBiopsy
✅bTMB AV paper = just published bit.ly/BP-bTMB
✅MRD tumor-informed AV paper = under peer review
✅NGS ctDNA AV protocols v2.0 = almost ready to submit
Next: tumor-agnostic #MRD AV pre-sub. More to come soon!
#LiquidBiopsy
September 24, 2025 at 2:59 PM
Our Analytical Validation (AV) efforts are on a roll. Check our Q3 updates:
✅bTMB AV paper = just published bit.ly/BP-bTMB
✅MRD tumor-informed AV paper = under peer review
✅NGS ctDNA AV protocols v2.0 = almost ready to submit
Next: tumor-agnostic #MRD AV pre-sub. More to come soon!
#LiquidBiopsy
✅bTMB AV paper = just published bit.ly/BP-bTMB
✅MRD tumor-informed AV paper = under peer review
✅NGS ctDNA AV protocols v2.0 = almost ready to submit
Next: tumor-agnostic #MRD AV pre-sub. More to come soon!
#LiquidBiopsy
Just published in the Journal of Molecular Diagnostics!
This new paper from the BLOODPAC #bTMB Working Group offers a framework for the #analyticalvalidation of bTMB tests, highlighting key technical and biological challenges.
👉https://www.sciencedirect.com/science/article/pii/S1525157825001850
This new paper from the BLOODPAC #bTMB Working Group offers a framework for the #analyticalvalidation of bTMB tests, highlighting key technical and biological challenges.
👉https://www.sciencedirect.com/science/article/pii/S1525157825001850
September 23, 2025 at 4:09 PM
Just published in the Journal of Molecular Diagnostics!
This new paper from the BLOODPAC #bTMB Working Group offers a framework for the #analyticalvalidation of bTMB tests, highlighting key technical and biological challenges.
👉https://www.sciencedirect.com/science/article/pii/S1525157825001850
This new paper from the BLOODPAC #bTMB Working Group offers a framework for the #analyticalvalidation of bTMB tests, highlighting key technical and biological challenges.
👉https://www.sciencedirect.com/science/article/pii/S1525157825001850